Crossmark

Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience

Crossref DOI link: https://doi.org/10.1186/s12913-025-12876-6

Published Online: 2025-05-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yaghoubi, Neda

Fatemi, Behzad

Ahmadi, Razieh

Metghalchi, Yalda

Shahrami, Bita

Vaezi, Mohammad

Rezaei, Soheila
License Information

Text and Data Mining valid from 2025-05-17

Version of Record valid from 2025-05-17
More Information

Article History

Received: 15 January 2025

Accepted: 12 May 2025

First Online: 17 May 2025

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below